Stanley R. Frankel, MD, FACP

Chief Medical Officer

Dr. Frankel is a hematologist-oncologist with extensive academic and industry experience in the research, clinical development, and commercialization of immuno-oncology and cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma.

Dr. Frankel was most recently the Senior Vice President, Cellular Therapy Development at Bristol-Myers Squibb (BMS) where he was responsible for late development portfolio of cellular therapy assets including Breyanzi® (lisocabtagene maraleucel) and Abecma® (idecabtagene vicleucel).. Prior to the BMS acquisition of Celgene, he was Corporate Vice President, Head, Immuno-Oncology & Cellular Therapy, Clinical Research and Development Head, Cell Therapy Clinical Center of Excellence at Celgene. While at Celgene he co-chaired the Hematology-Oncology Development Committee and served on the Hematology-Oncology Franchise Leadership Team. He served on Joint Steering and/or Joint Development Committees for alliances with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene. He is an independent member of the Board of Directors of Precision BioSciences.

Dr. Frankel has overseen bispecific antibody preclinical and clinical development in his prior roles as Vice President, Clinical Development at Micromet, and following the Amgen acquisition of Micromet and the bispecific T cell engager platform including Blincyto®, as Executive Director, Medical Sciences and Early Development Oncology Therapeutic Area Head. He had previously served in clinical development roles at Roche, Merck, and Genta.

Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. He completed his residency in internal medicine at Mount Sinai Hospital and his fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center where he was Chief Fellow. He has prior academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland prior to joining Columbia University Vagelos College of Physicians and Surgeons as Adjunct Associate Professor of Medicine in the Division of Hematology/Oncology.